Tanner Pharma Group uses cookies on its website. By continuing to access this website you are agreeing to Tanner Pharma Group's Data Privacy Policy. For more information, click here.

Tanner Pharma Group Executives to Present at 2015 BIO International

Presentations to Focus on Enhancing Access and Commercial Success in Challenging International Markets with Minimal Risk and Investment

CHARLOTTE, N.C. – Top executives from Tanner Pharma Group will speak at the largest life-science conference in the world, the 2015 BIO International Convention, scheduled for June 15-18 in Philadelphia. The presentations will provide key insights into enhancing product access and commercialization for pharmaceutical companies in challenging international markets.

On June 16, Carolina Cortez, Director of Tanner Pharma Group’s Licensing, Acquisition and Commercialisation Division (TannerLAC), will present “Overcoming Challenges in the Evolving Latin American Market.” Cortez’s presentation will address the complexities of penetrating the Latin American market through registration and promotion, and discuss solutions to commercializing pharmaceutical, biotech and healthcare products including partnering, licensing and targeted divestitures.

Then on June 17, Joshua Cooper, Director of Corporate Development for Tanner Pharma Group, will present “Enhancing Access; Minimizing Investment.” Cooper will share alternative strategies to unlocking value in lower priority markets where pharmaceutical firms often see demand for products.

With over 12 years of international pharmaceutical experience, as well as fluency in English, Spanish and Portuguese, Cortez has a proven ability to drive value in international markets. Under her leadership, TannerLAC provides pharmaceutical, biotech and healthcare companies with access to emerging markets while minimizing the risk, investment and resources necessary for companies to register, market and maximize sales in Latin America and other international markets.

Previously a member of the Bourne Partners investment banking team, Cooper combines his financial background with his global pharmaceutical commercial experience at Merck Sharpe & Dohme, Novartis, and Valeant. He oversees key strategic and commercial initiatives at Tanner as well as Global Access Programmes, including Named Patient Programmes, Expanded Access Programmes, Compassionate Use Programmes, and Emergency Supply allocations.

Both Tanner Pharma Group presentations will take place at 10 a.m. in the Exhibit Hall at the North Carolina Pavilion, booth 4235. Each 20-minute session will be followed by a 10-minute question and answer period. For more information, feel free to contact CCortez@TannerPharma.com or JCooper@TannerPharma.com directly. Both contacts will also be available for meetings through the BIO One-on-One PartneringTM system.

About Tanner Pharma Group

For over 16 years, Tanner Pharma Group has partnered with biopharmaceutical companies to provide turn-key commercialization solutions to increase patient access to medicines around the world. By partnering with Tanner Pharma, biotech and pharma companies are able to focus on their primary markets while ensuring that patients in international markets of need are receiving their products through a strictly controlled channel.

Tanner Pharma believes that access to medicines should have no borders and measures its value as a company based on the lives it helps to improve. With an unparalleled blend of local market knowledge, international supply chain expertise across more than 130 countries, and high regulatory compliance and quality standards, it provides tailored solutions to biopharmaceutical companies outside their core markets of focus.

Headquartered in the U.S., Tanner’s reach includes Europe, Northeast Asia, Southeast Asia, the Middle East, Australia, Canada and Latin America, including Brazil, Mexico, the Caribbean, Central America and all of South America.

For more information about Tanner Pharma Group, please visit www.tannerpharma.com.

Contact Us